论文部分内容阅读
目的观察阿托伐他汀对慢性心力衰竭(chronic heart failur,CHF)患者血清脂联素(adiponectin,APN)和有关心衰标志物的影响。方法测定症状基本得到控制的CHF患者在常规抗心衰基础上经阿托伐他汀治疗4周前后APN与NT-proBNP、TNF-α、IL-6水平。结果在常规抗心衰药物治疗基础上加用阿托伐他汀治疗4周,TNF-α、IL-6水平较对照组降低(P<0.05),APN和NT-proBNP水平差异无统计学意义(P>0.05)。结论短期应用阿托伐他汀治疗CHF患者,APN和NT-proBNP水平无变化。
Objective To observe the effect of atorvastatin on serum adiponectin (APN) and related heart failure markers in patients with chronic heart failure (CHF). Methods The levels of APN, NT-proBNP, TNF-α and IL-6 in CHF patients with basically controlled symptoms were measured before and 4 weeks after treatment with atorvastatin on the basis of conventional anti-heart failure. Results Compared with the control group, the levels of TNF-α and IL-6 in atherosclerotic heart treated with atorvastatin for 4 weeks were not significantly different (P <0.05), while the levels of APN and NT-proBNP were not significantly different P> 0.05). Conclusion Short-term atorvastatin treatment of patients with CHF, APN and NT-proBNP levels did not change.